The Hapa 862, from Hapa AG, is a modular, CMYK/spot-color inkjet printing system for the in-line packaging printing of foils and labels.
The Hapa 862, from Hapa AG, is a modular, CMYK/spot-color inkjet printing system for the in-line packaging printing of foils and labels. With its flexibility and scalability, it eases the manufacturer’s challenges of SKU and supply-chain complexities, frequent line changeovers, and evolving legislative requirements. The Hapa 862 is engineered in compliance with the stringent requirements of the pharmaceutical sector and follows current best practice in machinery and software design. Scalable and modular, the printing system can be integrated with customers’ existing packaging lines in top- or stand-mounted configurations, or alternatively, it can operate offline as a roll-to-roll machine.
The new EU track & trace legislation will require each pack to be identifiable with a unique on-pack code incorporating both machine-readable and human-readable elements. The Hapa 862 provides the solution to this challenge, printing artwork and variable data in a single pass at speeds up to 54 meters/minute on high-speed lines. Immediate UV-LED curing ensures the printed substrates or products are ready for onward processing.
Hapa AG is also showcasing at ACHEMA a new human machine interface (HMI) alongside the Hapa 862. Co-developed with other Coesia companies, the user interface is designed for usability and ease of integration into ERP and workflows. It simplifies batch set-up and minimizes training requirements in factories operating multiple lines of Hapa equipment.
Source: Hapa AG, Hall 3.0, Stand B95
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.